The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant tissues were in general negative. Most cases of breast, prostate and endometrial cancers as well as several colorectal, cervical and liver cancers showed moderate granular cytoplasmic positivity.
A majority of breast and prostate cancers as well as several malignant melanomas and ovarian cancers showed moderate cytoplasmic staining. Remaining malignancies were in general weakly stained or negative.
Weak to moderate cytoplasmic and occasional nuclear immunoreactivity was observed in most malignant tissues. Cases of prostate cancers and malignant melanomas were strongly positive. Lung, lymphoma, renal and liver cancers.
Malignant tissues were in most cases weakly stained or negative. Most Breast and prostate cancers as well as several colorectal and endometrial cancers showed moderate cytoplasmic positivity.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
